Rezultati pretrage - Baselga, Josè

Detaljiziraj rezultate
  1. 1
    Pharmacology in the Era of Targeted Therapies: The Case of PI3K Inhibitors

    Pharmacology in the Era of Targeted Therapies: The Case of PI3K Inhibitors od Toska, Eneda, Baselga, José

    Izdano 2016
    Preuzmi cijeli tekst Preuzmi cijeli tekst Preuzmi cijeli tekst
    Tekst
    Spremi u popis
    Spremljeno u:
  2. 2
    Targeted therapies for breast cancer

    Targeted therapies for breast cancer od Higgins, Michaela J., Baselga, José

    Izdano 2011
    Preuzmi cijeli tekst Preuzmi cijeli tekst Preuzmi cijeli tekst
    Tekst
    Spremi u popis
    Spremljeno u:
  3. 3
    Molecular Pathways: AXL, a Membrane Receptor Mediator of Resistance to Therapy

    Molecular Pathways: AXL, a Membrane Receptor Mediator of Resistance to Therapy od Scaltriti, Maurizio, Elkabets, Moshe, Baselga, José

    Izdano 2016
    Preuzmi cijeli tekst Preuzmi cijeli tekst Preuzmi cijeli tekst
    Tekst
    Spremi u popis
    Spremljeno u:
  4. 4
    Deconstructing feedback-signaling networks to improve anticancer therapy with mTORC1 inhibitors

    Deconstructing feedback-signaling networks to improve anticancer therapy with mTORC1 inhibitors od Carracedo, Arkaitz, Baselga, Jose, Pandolfi, Pier Paolo

    Izdano 2008
    Preuzmi cijeli tekst Preuzmi cijeli tekst
    Tekst
    Spremi u popis
    Spremljeno u:
  5. 5
    Treatment of HER2-Positive Metastatic Breast Cancer

    Treatment of HER2-Positive Metastatic Breast Cancer od Swain, Sandra M., Clark, Emma, Baselga, José

    Izdano 2015
    Preuzmi cijeli tekst Preuzmi cijeli tekst Preuzmi cijeli tekst
    Tekst
    Spremi u popis
    Spremljeno u:
  6. 6
    Implementing Genome-Driven Oncology

    Implementing Genome-Driven Oncology od Hyman, David M., Taylor, Barry S., Baselga, José

    Izdano 2017
    Preuzmi cijeli tekst Preuzmi cijeli tekst Preuzmi cijeli tekst
    Tekst
    Spremi u popis
    Spremljeno u:
  7. 7
    A view on drug resistance in cancer

    A view on drug resistance in cancer od Vasan, Neil, Baselga, José, Hyman, David M.

    Izdano 2019
    Preuzmi cijeli tekst Preuzmi cijeli tekst Preuzmi cijeli tekst
    Tekst
    Spremi u popis
    Spremljeno u:
  8. 8
    Synergy between trastuzumab and pertuzumab for human epidermal growth factor 2 (Her2) from colocalization: an in silico based mechanism

    Synergy between trastuzumab and pertuzumab for human epidermal growth factor 2 (Her2) from colocalization: an in silico based mechanism od Fuentes, Gloria, Scaltriti, Maurizio, Baselga, José, Verma, Chandra S

    Izdano 2011
    Preuzmi cijeli tekst Preuzmi cijeli tekst Preuzmi cijeli tekst
    Tekst
    Spremi u popis
    Spremljeno u:
  9. 9
    Advances in the management of HER2-positive early breast cancer

    Advances in the management of HER2-positive early breast cancer od Baselga, José, Coleman, Robert E., Cortés, Javier, Janni, Wolfgang

    Izdano 2017
    Preuzmi cijeli tekst Preuzmi cijeli tekst Preuzmi cijeli tekst
    Tekst
    Spremi u popis
    Spremljeno u:
  10. 10
    Pancancer modelling predicts the context-specific impact of somatic mutations on transcriptional programs

    Pancancer modelling predicts the context-specific impact of somatic mutations on transcriptional programs od Osmanbeyoglu, Hatice U., Toska, Eneda, Chan, Carmen, Baselga, José, Leslie, Christina S.

    Izdano 2017
    Preuzmi cijeli tekst Preuzmi cijeli tekst Preuzmi cijeli tekst
    Tekst
    Spremi u popis
    Spremljeno u:
  11. 11
    Unconventional Secretion is a Major Contributor of Cancer Cell Line Secretomes

    Unconventional Secretion is a Major Contributor of Cancer Cell Line Secretomes od Villarreal, Laura, Méndez, Olga, Salvans, Cándida, Gregori, Josep, Baselga, José, Villanueva, Josep

    Izdano 2013
    Preuzmi cijeli tekst Preuzmi cijeli tekst Preuzmi cijeli tekst
    Tekst
    Spremi u popis
    Spremljeno u:
  12. 12
    The Carboxy-terminal Cysteine of the Tetraspanin L6 Antigen Is Required for Its Interaction with SITAC, a Novel PDZ Protein

    The Carboxy-terminal Cysteine of the Tetraspanin L6 Antigen Is Required for Its Interaction with SITAC, a Novel PDZ Protein od Borrell-Pagès, Maria, Fernández-Larrea, Juan, Borroto, Aldo, Rojo, Federico, Baselga, José, Arribas, Joaquín

    Izdano 2000
    Preuzmi cijeli tekst Preuzmi cijeli tekst
    Tekst
    Spremi u popis
    Spremljeno u:
  13. 13
    Proteomic Identification of Desmoglein 2 and Activated Leukocyte Cell Adhesion Molecule as Substrates of ADAM17 and ADAM10 by Difference Gel Electrophoresis

    Proteomic Identification of Desmoglein 2 and Activated Leukocyte Cell Adhesion Molecule as Substrates of ADAM17 and ADAM10 by Difference Gel Electrophoresis od Bech-Serra, Joan J., Santiago-Josefat, Belén, Esselens, Cary, Saftig, Paul, Baselga, José, Arribas, Joaquín, Canals, Francesc

    Izdano 2006
    Preuzmi cijeli tekst Preuzmi cijeli tekst Preuzmi cijeli tekst
    Tekst
    Spremi u popis
    Spremljeno u:
  14. 14
    Biosynthesis of tumorigenic HER2 C-terminal fragments by alternative initiation of translation

    Biosynthesis of tumorigenic HER2 C-terminal fragments by alternative initiation of translation od Anido, Judit, Scaltriti, Maurizio, Bech Serra, Joan Josep, Josefat, Belén Santiago, Rojo Todo, Federico, Baselga, José, Arribas, Joaquín

    Izdano 2006
    Preuzmi cijeli tekst Preuzmi cijeli tekst Preuzmi cijeli tekst
    Tekst
    Spremi u popis
    Spremljeno u:
  15. 15
    Differential Receptor Tyrosine Kinase PET Imaging for Therapeutic Guidance

    Differential Receptor Tyrosine Kinase PET Imaging for Therapeutic Guidance od Wehrenberg-Klee, Eric, Turker, N. Selcan, Heidari, Pedram, Larimer, Benjamin, Juric, Dejan, Baselga, José, Scaltriti, Maurizio, Mahmood, Umar

    Izdano 2016
    Preuzmi cijeli tekst Preuzmi cijeli tekst Preuzmi cijeli tekst
    Tekst
    Spremi u popis
    Spremljeno u:
  16. 16
    Treatment of older patients with HER2-positive metastatic breast cancer with pertuzumab, trastuzumab, and docetaxel: subgroup analyses from a randomized, double-blind, placebo-controlled phase III trial (CLEOPATRA)

    Treatment of older patients with HER2-positive metastatic breast cancer with pertuzumab, trastuzumab, and docetaxel: subgroup analyses from a randomized, double-blind, placebo-cont... od Miles, David, Baselga, José, Amadori, Dino, Sunpaweravong, Patrapim, Semiglazov, Vladimir, Knott, Adam, Clark, Emma, Ross, Graham, Swain, Sandra M.

    Izdano 2013
    Preuzmi cijeli tekst Preuzmi cijeli tekst Preuzmi cijeli tekst
    Tekst
    Spremi u popis
    Spremljeno u:
  17. 17
    Cetuximab and Radiotherapy in Laryngeal Preservation for Cancers of the Larynx and Hypopharynx: A Secondary Analysis of a Randomized Clinical Trial

    Cetuximab and Radiotherapy in Laryngeal Preservation for Cancers of the Larynx and Hypopharynx: A Secondary Analysis of a Randomized Clinical Trial od Bonner, James, Giralt, Jordi, Harari, Paul, Spencer, Sharon, Schulten, Jeltje, Hossain, Anwar, Chang, Shao-Chun, Chin, Steve, Baselga, José

    Izdano 2016
    Preuzmi cijeli tekst Preuzmi cijeli tekst Preuzmi cijeli tekst
    Tekst
    Spremi u popis
    Spremljeno u:
  18. 18
    TARGETING THE MUC1-C ONCOPROTEIN DOWNREGULATES HER2 ACTIVATION AND ABROGATES TRASTUZUMAB RESISTANCE IN BREAST CANCER CELLS

    TARGETING THE MUC1-C ONCOPROTEIN DOWNREGULATES HER2 ACTIVATION AND ABROGATES TRASTUZUMAB RESISTANCE IN BREAST CANCER CELLS od Raina, Deepak, Uchida, Yasumitsu, Kharbanda, Akriti, Rajabi, Hasan, Panchamoorthy, Govind, Jin, Caining, Kharbanda, Surender, Scaltriti, Maurizio, Baselga, Jose, Kufe, Donald

    Izdano 2013
    Preuzmi cijeli tekst Preuzmi cijeli tekst Preuzmi cijeli tekst
    Tekst
    Spremi u popis
    Spremljeno u:
  19. 19
    Molecular Features and Survival Outcomes of the Intrinsic Subtypes Within HER2-Positive Breast Cancer

    Molecular Features and Survival Outcomes of the Intrinsic Subtypes Within HER2-Positive Breast Cancer od Prat, Aleix, Carey, Lisa A., Adamo, Barbara, Vidal, Maria, Tabernero, Josep, Cortés, Javier, Parker, Joel S., Perou, Charles M., Baselga, José

    Izdano 2014
    Preuzmi cijeli tekst Preuzmi cijeli tekst Preuzmi cijeli tekst
    Tekst
    Spremi u popis
    Spremljeno u:
  20. 20
    An implantable microdevice to perform high-throughput in vivo drug sensitivity testing in tumors

    An implantable microdevice to perform high-throughput in vivo drug sensitivity testing in tumors od Jonas, Oliver, Landry, Heather M., Fuller, Jason E., Santini, John T., Baselga, Jose, Tepper, Robert I., Cima, Michael J., Langer, Robert

    Izdano 2015
    Preuzmi cijeli tekst Preuzmi cijeli tekst Preuzmi cijeli tekst
    Tekst
    Spremi u popis
    Spremljeno u:

Alati za pretragu: